RT Journal Article
SR Electronic
T1 Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.09.20246389
DO 10.1101/2020.12.09.20246389
A1 Roberts, Ivayla
A1 Muelas, Marina Wright
A1 Taylor, Joseph M.
A1 Davison, Andrew S.
A1 Xu, Yun
A1 Grixti, Justine M.
A1 Gotts, Nigel
A1 Sorokin, Anatolii
A1 Goodacre, Royston
A1 Kell, Douglas B.
YR 2021
UL http://medrxiv.org/content/early/2021/07/12/2020.12.09.20246389.abstract
AB The diagnosis of COVID-19 is normally based on the qualitative detection of viral nucleic acid sequences. Properties of the host response are not measured but are key in determining outcome. Although metabolic profiles are well suited to capture host state, most metabolomics studies are either underpowered, measure only a restricted subset of metabolites, compare infected individuals against uninfected control cohorts that are not suitably matched, or do not provide a compact predictive model.Here we provide a well-powered, untargeted metabolomics assessment of 120 COVID-19 patient samples acquired at hospital admission. The study aims to predict the patient’s infection severity (i.e., mild or severe) and potential outcome (i.e., discharged or deceased).High resolution untargeted LC-MS/MS analysis was performed on patient serum using both positive and negative ionization modes. A subset of 20 intermediary metabolites predictive of severity or outcome were selected based on univariate statistical significance and a multiple predictor Bayesian logistic regression model was created. The predictors were selected for their relevant biological function and include cytosine and ureidopropionate (indirectly reflecting viral load), kynurenine (reflecting host inflammatory response), and multiple short chain acylcarnitines (energy metabolism) among others.Currently, this approach predicts outcome and severity with a Monte Carlo cross validated area under the ROC curve of 0.792 (SD 0.09) and 0.793 (SD 0.08), respectively. A blind validation study on an additional 90 patients predicted outcome and severity at ROC AUC of 0.83 (CI 0.74 – 0.91) and 0.76 (CI 0.67 – 0.86). Prognostic tests based on the markers discussed in this paper could allow improvement in the planning of COVID-19 patient treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank the UK BBSRC (grant BB/V003976/1) and the Novo Nordisk Foundation (grant NNF10CC1016517) for financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained to use the samples included in the study from the Health Regulatory Authority and Health and Care Research Wales (HCRW), and the North-West England Research Ethics (ref: 20/NW/0332).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMTBLS2997 www.ebi.ac.uk/metabolights/ https://www.ebi.ac.uk/metabolights/ AEX-LC-MS/MSanion-exchange LC-MSAFatrial fibrillationALTalanine aminotransferaseARDSacute respiratory distress syndromeAUCarea under the curveBMIbody mass indexBPsystolic blood pressureCIconfidence intervalCOVID-19Coronavirus disease 2019CPAPcontinuous positive airw ay pressureCRPC-reactive proteinCRScytokine release stormsCVcoefficient of variationeGFRestimated glomerular filtration rateESIelectrospray ionizationFCfold changeFDRfalse discoverFIO2fraction of inspired oxygenGC-MSgas hromatography mass spectrometryGCSGlasgow coma scaleGLMgeneralized inear modelsHbhaemoglobin evelsHCThaematocritIHDischaemic heart diseaseIQAinter-batch quality assuranceLC-MSliquid chromatography mass spectrometryLC-MS/MSliquid chromatography tandem mass spectrometryLFClog fold changeLymphslymphocyte countMB-PCAmultiblock PCAMSIMetabolomics Standards nitiativeMSMLmass spectrometry metabolite libraryNEWSnational early warning scoreNICEnational institute for health and care excellenceNMRnuclear magnetic resonanceORodds ratioPCAprincipal component analysisPCRpolymerase chain reactionPLTsplatelets countQCquality controlRLUHroyal Liverpool university hospitalROCreceiver operating characteristicrRNAribosomal RNARTretention timeRTPCRreverse transcription PCRSARS-CoV-2severe acute respiratory syndrome coronavirus-2SDstandard deviationSOBshortness of breathWBCwhite blood cell count